Abbvie 3Q Revenues: $14.5 billion (+4%) 3Q Earnings: $1.6 billion (-12%) YTD Revenues: $41.2 billion (+3%)  YTD Earnings: $4.3 billion (+6%) Comments: Humira sales were $2.2 billion, down 37% in the quarter. Skyrizi sales were $3.2 billion, an increase of 51%. Rinvoq revenues were $1.6 billion, up 45%. Imbruvica sales were $828 million, down 9%. Venclexta sales were $677 million, up 15%.Elahere sales were $139 million. Botox Therapeutic sales were $848 million, up 13%. Vraylar revenues were...